Why the study?
Does continuation of warfarin therapy during pacemaker or ICD implantation increase the risk of major bleeding or hematomas in orally anticoagulated patients?
Population
47 patients presenting for device implantation treated with warfarin.
Design
Cohort
Follow-up
6 weeks
Authors
Loading...
No bleeding events seen with continued warfarin; supports feasibility but leaves open randomized confirmation.
Does continuation of warfarin therapy during pacemaker or ICD implantation increase the risk of major bleeding or hematomas in orally anticoagulated patients?
Device implantation can be safely performed in patients continuing warfarin therapy with an INR < 3.5, without significant bleeding complications.
Ayman S. Al-Khadra (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: